NCT05029076View on ClinicalTrials.gov

Human Bioequivalence Test of Liraglutide Injection

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

May 21, 2019

Primary Completion Date

June 1, 2019

Study Completion Date

July 1, 2019

Conditions
Type 2 Diabetes
Interventions
DRUG

Liraglutide injection

Human glucagon-like peptides-1 analogue

DRUG

Victoza

Human glucagon-like peptides-1 analogue

Trial Locations (1)

130021

Affiliated Hospital of Changchun University of Traditional Chinese Medicine, Changchun

Sponsors
All Listed Sponsors
lead

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

INDUSTRY